Artelo Pain Inhibitor Shows Promise in Publication

Artelo has announced a peer-reviewed publication supporting its FABP5 inhibitor, ART26.12, as a novel pain treatment. The study highlights the drug's potentially first-in-class profile, differentiating it from existing therapies. This positive data precedes a planned multiple ascending dose study later this year, following a successful Phase 1 single ascending dose study. The findings suggest ART26.12 could offer a significant advancement in pain management.